Literature DB >> 2654471

Molecular mechanisms of oncogenesis.

T A Seemayer1, W K Cavenee.   

Abstract

Cellular oncogenes (c-oncs) have been highly conserved throughout evolution and subserve important roles in growth and development. Both in development and the neoplastic state, c-oncs appear to collaborate rather than function independently. Cellular oncogenes are activated in the neoplastic process by four (nonviral) mechanisms; (a) chromosomal translocations; (b) gene amplifications; (c) point mutations; and (d) DNA rearrangements. The timing of c-onc gene product expression may be as important in oncogenesis as the level of expression. At this writing, mutant oncogenes have not been shown to be inherited. Oncogene amplification, if important in oncogenesis, is more likely to be involved with tumor progression rather than initiation. Chromosomal/molecular aberrations tend to be characteristic for a given type of cancer. These genetic alterations are often situated near heritable fragile sites, tumor-suppressor gene loci and/or oncogene loci. Similar molecular mechanisms involving translocations and inversions may underly the common T and B cell neoplasms. The loss/inactivation of both normal alleles at a locus thought to encode for tumor-suppressing activities (antioncogenes) may represent an event common to many childhood and adult neoplasms. The consistency and cell specificity with which this has been identified is consistent with a role for such genes in cellular differentiation. At this writing, the paradigm for such a controlling locus is 13q14, the site of the retinoblastoma gene. Based on recent studies in familial and sporadic Wilms' tumor which suggest etiological heterogeneity, theoretical modifications of the carcinogenesis model which has been central to understanding retinoblastoma may soon be forthcoming to explain molecular mechanisms operative in other cancer. The role of genomic imprinting in carcinogenesis is only recently being explored. Further study of this process may prove to be a fruitful area of future research.

Entities:  

Mesh:

Year:  1989        PMID: 2654471

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  7 in total

Review 1.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

Review 2.  The current state of oncogenes and cancer: experimental approaches for analyzing oncogenetic events in human cancer.

Authors:  P J Chiao; F Z Bischoff; L C Strong; M A Tainsky
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

3.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

4.  Loss of heterozygosity of the L-myc oncogene in human breast tumors.

Authors:  I Bieche; M H Champeme; G Merlo; C J Larsen; R Callahan; R Lidereau
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

5.  Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: two additional regions identified.

Authors:  C S Cropp; R Lidereau; G Campbell; M H Champene; R Callahan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 6.  Oncogenes: present status.

Authors:  T S Vats; A Emami
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

7.  Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors.

Authors:  B M Kacinski; D Carter; E I Kohorn; K Mittal; R S Bloodgood; J Donahue; C A Kramer; D Fischer; R Edwards; S K Chambers
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.